The global cancer cachexia market size is expected to reach USD 3.43 billion by 2032, exhibiting the CAGR of 4.2% during the forecast period.
he Cancer Cachexia Market is growing as increasing awareness of this condition, along with advancements in medical research, is driving the demand for effective treatments. Given the prevalence of cancer and the lack of effective treatments for cachexia, this market is expected to see substantial growth in the coming years.
Key Trends in the Market
- Biologic Therapies and Novel Drug Development:
- There is a growing focus on biologics, including monoclonal antibodies and protein-based therapies, as potential treatments for cancer cachexia. These therapies aim to target the inflammatory cytokines and pathways involved in cachexia development, offering new hope for patients.
- Multimodal Treatment Approaches:
- A growing trend in the treatment of cancer cachexia is the use of multimodal therapy. This approach combines pharmacological interventions with nutritional support, exercise, and physical therapy to help manage muscle wasting and improve patient quality of life.
- Personalized Medicine:
- With advances in genomics and molecular biology, personalized medicine is gaining traction in cancer cachexia treatment. By tailoring treatments based on individual genetic and molecular profiles, therapies can be more effective in treating cachexia in different types of cancer patients.
Download Free Sample PDF Copy of the Report:
https://www.polarismarketresearch.com/industry-analysis/cancer-cachexia-market/request-for-sample
Some of the major players operating in the global market include:
- AbbVie Inc. (US)
- Actimed Therapeutics (UK)
- Aeterna Zentaris Inc. (Canada)
- ANI Pharmaceuticals Inc. (US)
- Aphios Corporation (US)
- Aveo Pharmaceuticals Inc. (US)
- Bristol-Myers Squibb Company (US)
- Helsinn Group (Switzerland)
- Hikma Pharmaceuticals PLC (UK)
𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐚𝐥 𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬:
The research study includes segmental analysis that divides the market into distinct groups or segments based on common characteristics. With market segmentation, businesses can identify specific customer groups that are more likely to be interested in specific products or services. Also, it enables these businesses to focus their marketing efforts and resources more efficiently, leading to higher conversion rates and improved return on investment. Furthermore, segmentation analysis helps companies develop personalized products or services, which can result in increased customer loyalty and improved customer satisfaction.
Cancer Cachexia, Therapeutics Outlook (Revenue – USD Billion, 2024 – 2032)
- Progestogens
- Corticosteroids
- Combination Therapy
- Others
Cancer Cachexia, Mechanism of Action Outlook (Revenue – USD Billion, 2024 – 2032)
- Appetite Stimulators
- Weight Loss Stabilizers
Cancer Cachexia, Distribution Channel Outlook (Revenue – USD Billion, 2024 – 2032)
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Recent Developments in the Industry
- In January 2024, Meta Fines announced that they had signed a licensing-out agreement with BMI Korea for their cancer cachexia drug ASCA101_CC. According to this agreement, BMI Korea will hold the rights of global technology transfer of ASCA101_CC along with Meta Fines and will also have the right to license products in a few countries.
- In January 2023, Endevica Bio closed a USD 10 million Series B financing for the advancement or development of TCMC07 for treating cancer cachexia. The funding will allow the company to advance its research & development capabilities and help it develop a treatment for the patient population suffering from cachexia.
The Cancer Cachexia Market is poised for significant growth due to the increasing prevalence of cancer, growing awareness of cachexia, and the expanding research and development activities aimed at finding effective therapies. The market remains challenged by the complex nature of the disease, but continued progress in understanding its underlying mechanisms and the development of new treatments are expected to drive market growth. Companies and research institutions focusing on innovative therapies, including biologics, anti-inflammatory agents, and nutritional support, will be key players in shaping the future of cancer cachexia treatment.